Kiniksa Pharmaceuticals International (KNSA) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Kiniksa Pharmaceuticals International (NASDAQ: KNSA):

• 10/28/2026 – Kiniksa Pharmaceuticals International was downgraded by Weiss Ratings from “buy (b-)” to “hold (c-)”.
• 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by The Goldman Sachs Group from $90.00 to $101.00. They now have a “buy” rating on the stock.
• 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wedbush from $99.00 to $102.00. They now have an “outperform” rating on the stock.
• 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wells Fargo & Company from $87.00 to $110.00. They now have an “overweight” rating on the stock.
• 10/8/2026 – Kiniksa Pharmaceuticals International was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 9/30/2026 – Kiniksa Pharmaceuticals International is now covered by Wells Fargo & Company. They set an “overweight” rating and a $87.00 price target on the stock.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.